How H-1B Visa Changes Could Benefit Indian Professionals and Not Outsourcing & Technology Companies

Changes in Skills Visa Policy in the U.S. Could Benefit Indian Professionals but Raise Labor Costs for Companies

By Ignatius Chithelen 

Knowledge@Wharton April 26, 2018







President Trump has issued an executive order directing some U.S. agencies to review the nonimmigrant, H-1B work visa policies, which at present allow companies to hire “skilled” foreign workers when employers say they cannot find qualified Americans. Trump has questioned the impact of the program, saying that it represses American wages by paying foreign workers less. The U.S. issues 85,000 H-1B visas annually, and extends or reissues another 100,000 visas, according to Forbes. Last year, nearly 127,000 visas went to Indian nationals, about 21,700 to Chinese workers and 2,540 to Mexicans to round out the top three.
Should the review lead to curtailing the visas, on first glance it looks likely to hit Indian professionals — and Indian tech companies in particular — the hardest. But in this opinion piece, Ignatius Chithelen argues that some Indian visa holders could actually end up ahead. He is the author of Six Degrees of Education: From Teaching in Mumbai to Investment Research in New York, and the founder and managing partner of Banyan Tree Capital Management.






Comments

Post a Comment

Popular posts from this blog

Satish Mehta CEO of Emcure Pharmaceuticals and a Drug Price-Fixing Scandal

The Billionaire And The Drug Price-Fixing Scandal. Forbes article Satish Mehta founded Emcure Pharmaceuticals in 1981. In 2011 Emcure bought U.S. based Heritage Pharmaceuticals founded by Jeffrey Glazer. In 2016 Heritage had U.S. sales of $265 million, 40% of Emcure's total sales. An article in Forbes , by Nathan Vardi and Nazneen Karmali April 25, 2017, says that, " In September 2015, Satish Mehta, the billionaire chief executive of the Indian drug company Emcure Pharmaceuticals, wrote an effusive email congratulating Jeffrey Glazer, the CEO of his U.S. crown jewel, Heritage Pharmaceuticals, on a job well done. "In a short span of 4.5 years, you have taken Heritage to another level," Mehta wrote, adding that he considered Glazer to be "an integral part of our family." In January this year, the article continues, "Glazer pleaded guilty to violating U.S. antitrust law by conspiring with manufacturers to fix the prices of generic drugs. Glazer is
Read more

Why Second Generation Indians in U.S. will not be as Successful:

Image
The Bamboo Ceiling for Asians at U.S. Colleges Extract from "Six Degrees of Education: From Teaching in Mumbai to Investment Research in New York" by Ignatius Chithelen  Published by India Today Online August 3, 2016  Why Second Generation Indians in the U.S. will not be as Successful S ince the 1980s, several million Indians have studied at U.S. colleges. Over a million have stayed on in the U.S. through employment visas and many of them have become successful as professionals and some as entrepreneurs. They include chief executives of major U.S. companies such as Sundar Pichai at Google, Satya Nadella at Microsoft, Shantanu Narayen at software vendor Adobe, Indra Nooyi at Pepsico and Rakesh Sachdev of chemicals and bio-chemicals supplier Sigma-Aldrich. Businesses founded or co-founded by Indians in the U.S. include Cascade Communications, Daisy Systems, Epitome, Hotmail, Junglee, Morphotek, Solar Junction and TIBCO Software.  Some Indian en
Read more